Fig. 5

Depletion of tumor-infiltrated Ly6C^high monocytes dampens RvD1 anticancer effects. a Scheme showing in vivo transplantation of C3 cells in C57BL/6 mice and treatment with vehicle or RvD1 (1 μg/kg) plus vehicle or the CCR2 antagonist SC-202525 (2 mg/kg). b Percentage of intratumor classical monocytes as determined by FACS analysis of single-cell dissociated tumors. Data are expressed as percentage of CD45⁺ leukocytes. n = 5–6 mice per group. *, P < 0.05 (two-way ANOVA with Tukey’s multiple comparison test). c Growth of tumors from C3 cells transplanted in syngeneic mice and treated with vehicle/RvD1 plus vehicle/CCR2 inhibitor. Data are expressed as volume fold change as compared to the initial tumor volume at the start of treatments (T1). n = 5–6 mice per group. *, P < 0.05 RvD1 vs CCR2 antagonist+RvD1 at day 11. ****, P < 0.0001 vehicle vs RvD1 at day 11 (two-way ANOVA and Tukey’s multiple comparison test). d Kaplan-Meier curve survival analysis reporting the time for tumors to reach a volume of 1500 mm³ (humanized endpoint). n = 5–6 mice tumors per group. *, P < 0.05 (Log-rank Mantel-Cox test)